Posted On: 08/12/2014 1:27:47 PM
Post# of 102755
VPRO HUGE $100-200 M VALUE >>Viropro estimates the combined, aggregate realizable value of its biosimilars portfolio to be in the range of $33 million to $42 million, depending upon market dynamics of the individual products.
The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue run rate of $60–$150 million for Viropro within 10 years. The partnership is planning to launch its first product by late 2014.
The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue run rate of $60–$150 million for Viropro within 10 years. The partnership is planning to launch its first product by late 2014.
(0)
(0)
